Subscribe to Search results

Dr Kenneth Calman, CMO, was quoted in a Department of Health press release as saying he was satisfied that there was no scientific evidence of a link between meat eating and development of CJD,

Published on:

Recombinant was made available for all patients in Wales from 1997.

Published on:

In a background note for the House of Commons, it was stated that the Secretary of State had agreed to subsidise the additional cost of moving from plasma-derived Factor 8 to the commercial synthetic product, which could take a number of years.

Published on:

The Scottish Office made sufficient funding available for recombinant Factor 8 for young or new patients, but in due course this was to extend to all patients.

Published on:

An interim trust was set up in April 2001 and interim payments of £25,000 would be made to families of those who had been diagnosed with vCJD.

Published on:

In September 2004, patients with bleeding disorders were informed about vCJD by their haemophilia centre and given an opportunity to discuss the implications and given the option to find out if they had received an implicated batch if they wished.

Published on:

In the CJDIP document on the management of possible exposure to CJD through medical procedures, the section on managing blood incidents had been greyed out as it had not yet been finalised.

Published on:

It was only in the financial year 2004/5 that all patients with Haemophilia A in the UK were treated with recombinant Factor 8.

Published on:

In a paper published by the Department of Health into research on a link between new variant CJD and BSE, the publication of the latest scientific advice concluded that the evidence that had accumulated since March 1996 was consistent with the hypothesis that nvCJD was caused by exposure to the BSE agent.

Published on:

The Lothian Research Ethics Committee was where the NCJDSU had to apply to for ethical clearance for proposed retrospective study to examine the possible link between CJD and blood transfusion, known at the TMER study (Transfusion Medicine Epidemiology Review) on the condition that anyone traced as a result of the study, would not be told of their exposure.

Published on:

A study showed that there was a prevalence of infection of about 1 in 4000 people, albeit from a limited sized study.

Published on:

The Committee on Safety of Medicines recommended that blood products should not be sourced from UK plasma, due to the theoretical risk that nvCJD could be transmitted by blood products which could not be discounted.

Published on:

The chairman of the Spongiform Encephalopathy Advisory Committee reported he had received a letter from Mr and Mrs Churchill, the parents of one of the nvCJD victims, asking for SEAC to consider whether there was a causal link between BSE and nvCJD.

Published on:

A risk assessment for the transmission of vCJD via surgical instruments was produced by the Department of Health in January 2001.

Published on:

The Spongiform Encephalopathy Advisory Committee concluded that the position statement on research into a link between BSE and nvCJD should not create expectation of proof of causative, although a link had been made between the two.

Published on:

In the journal article titled "The same prion strain causes vCJD and BSE", it was stated that studies now strongly supported the hypothesis that vCJD was causally related to BSE.

Published on:

SEAC recommended that the NBA should take steps towards leucodepletion of blood as far as practicable, pending results of an assessment of the risk of transmitting vCJD by this means.

Published on:

The EU Committee on Proprietary Medicinal Products to which the UK had recommended a policy of recall if a plasma pool was found to have been made in part from a donation from someone who had subsequently developed vCJD, agreed there should be a recall and SEAC agreed the surveillance until would set up a procedure to report cases.

Published on:

Professor Will of NCJDRSU made an application to reconsider ethical approval for the TMER on the basis it was unethical not to do the study, because it might be the only mechanism of identifying transmission of vCJD through blood and blood products.

Published on:

The Lothian Research Ethics Committee reinstated approval for TMER on the basis that the decision whether to inform someone identified as at risk by the TMER was left to the appropriate health authority.

Published on: